Cibus, Inc.
NASDAQ:CBUS · NASDAQ Capital Market
-$0.02 today
Vol 0.11M · Avg 0.52M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-582.2%
avg -160.2%
ROIC
-23.2%
avg -59.6%
ROA
-41.7%
avg -53.4%
Analysis
ROIC is currently the strongest return metric at -23.2% versus its period average of -59.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rory Balfour Riggs | Co-Founder & Director | $1.09M | — | 73 | $77,586.00 | 0.17% |
Peter Beetham | Co-Founder, Interim Chief Executive Officer, President, Chief Operating Officer & Director | $630,579.00 | — | 63 | $686,825.00 | 1.51% |
Gregory F. Gocal | Co-Founder, Chief Scientific Officer & Executive Vice President | $455,021.00 | — | 57 | $422,890.00 | 0.93% |
Jason Stokes | Chief Administrative Officer, General Counsel & Corporate Secretary | $439,712.00 | — | 55 | $167,865.00 | 0.37% |
Cornelis Broos | Chief Financial Officer | $238,983.00 | — | 54 | $154,275.00 | 0.34% |
Rosa Cheuk Kim | Senior Vice President of Legal | — | — | — | — | — |
Noel Sauer | Senior Vice President of Research | — | — | 59 | $139,879.00 | 0.31% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +163.5% | +43.8% (11yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +163.5% over three years. Forward estimates point to Revenue at +43.8% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Who manages CBUS?
Cibus, Inc. (CBUS) lists 7 active executives. The top listed executive is Peter Beetham, Co-Founder, Interim Chief Executive Officer, President, Chief Operating Officer & Director.
Are CBUS insiders buying or selling?
Recent insider activity shows net buying of $29.85M.
Explore More
Continue the stock analysis
Jump to another research area for this company.